48,830
edits
(→Sarcomas: more) |
m (+neuropath) |
||
Line 104: | Line 104: | ||
*TTF-1. | *TTF-1. | ||
===Pancreas=== | |||
*CK17 - approx. 50% of [[pancreas|pancreatico]]biliary adenocarcinomas & patchy.<ref name=pmid11345833>{{cite journal |author=Goldstein NS, Bassi D |title=Cytokeratins 7, 17, and 20 reactivity in pancreatic and ampulla of vater adenocarcinomas. Percentage of positivity and distribution is affected by the cut-point threshold |journal=Am. J. Clin. Pathol. |volume=115 |issue=5 |pages=695–702 |year=2001 |month=May |pmid=11345833 |doi=10.1309/1NCM-46QX-3B5T-7XHR |url=}}</ref> | |||
*CK19.<ref name=pmid18318589>{{cite journal |author=Geller SA, Dhall D, Alsabeh R |title=Application of immunohistochemistry to liver and gastrointestinal neoplasms: liver, stomach, colon, and pancreas |journal=Arch. Pathol. Lab. Med. |volume=132 |issue=3 |pages=490–9 |year=2008 |month=March |pmid=18318589 |doi= |url=}}</ref> | |||
===Neuropathology=== | |||
General: | |||
*S-100. | |||
Glial: | |||
*GFAP. | |||
Neuronal: | |||
*Synaptophysin. | |||
*Chromogranin. | |||
Specific entities: | |||
*EMA +ve: meningioma, ependymomas (cytoplasm dot-like).<ref name=Ref_PSNP12>{{PSNP|12}}</ref> | |||
==Miscellaneous== | |||
===Macrophages=== | ===Macrophages=== | ||
*CD68. | *CD68. | ||
Line 110: | Line 129: | ||
Less common: | Less common: | ||
*HAM56.<ref name=pmid10574605>{{cite journal |author=Pernick NL, DaSilva M, Gangi MD, Crissman J, Adsay V |title="Histiocytic markers" in melanoma |journal=Mod. Pathol. |volume=12 |issue=11 |pages=1072–7 |year=1999 |month=November |pmid=10574605 |doi= |url=}}</ref> | *HAM56.<ref name=pmid10574605>{{cite journal |author=Pernick NL, DaSilva M, Gangi MD, Crissman J, Adsay V |title="Histiocytic markers" in melanoma |journal=Mod. Pathol. |volume=12 |issue=11 |pages=1072–7 |year=1999 |month=November |pmid=10574605 |doi= |url=}}</ref> | ||
==One organ vs. another== | ==One organ vs. another== |
edits